{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:16:01Z","timestamp":1790972161234,"version":"4.1.0"},"reference-count":60,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"],"award-info":[{"award-number":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00050"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00050"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WS1695414"],"award-info":[{"award-number":["WS1695414"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Background: Cardiovascular (CV) morbidity, mortality, and metabolic syndrome are associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Here, lipids and other metabolic markers in relation to vascular function and clinical markers were evaluated in RA and AS patients undergoing one-year anti-TNF therapy. Patients and methods: Fifty-three patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 17 AS patients treated with ETN were included in a 12-month follow-up study. Various lipids, paraoxonase (PON) and arylesterase (ARE) activities, myeloperoxidase (MPO) and adipokine levels were determined overtime. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. Results: Anti-TNF therapy decreased ARE activity, MPO, adiponectin, and chemerin levels after 12 months (p &lt; 0.05). Lipids, PON activity, and leptin remained unchanged. Regression analyses suggested variable associations of IMT, PWV, and FMD with ARE, MPO, leptin, and lipids (p &lt; 0.05). On the other hand, these metabolic parameters were significantly associated with disease duration, CV history, CRP, obesity, PWV, and IMT (p &lt; 0.05). One-year anti-TNF treatment together with baseline leptin (p = 0.039) or CRP (p = 0.016) levels determined 12 months of lipid changes overtime. TNF inhibition together with baseline disease activity determined ARE activity changes (p = 0.046). Anti-TNF therapy and baseline chemerin levels determined IMT changes overtime (p = 0.003). Conclusions: Assessment of various metabolic parameters together with disease activity, CRP, and ultrasound-based techniques may exert additional value in determining CV burden and in monitoring the effects of biologics on preclinical vascular pathophysiology.<\/jats:p>","DOI":"10.3390\/biom11101535","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T16:43:55Z","timestamp":1634575435000},"page":"1535","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-\u03b1 Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology"],"prefix":"10.3390","volume":"11","author":[{"given":"Monika","family":"Cz\u00f3kolyov\u00e1","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Pusztai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"V\u00e9gh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Szentp\u00e9teri","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, Department of Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Hamar","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Szamosi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Hodosi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Domj\u00e1n","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Sz\u00e1nt\u00f3","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"},{"name":"Department of Sports Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Kerekes","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Department of Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Seres","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, Department of Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-9595","authenticated-orcid":false,"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, Department of Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Paragh","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, Department of Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Szekanecz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Sz\u0171cs","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"Eular recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.berh.2016.10.006","article-title":"Cardiovascular disease in inflammatory rheumatic diseases","volume":"30","author":"Castaneda","year":"2016","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","article-title":"Cardiovascular comorbidity in rheumatic diseases","volume":"11","author":"Nurmohamed","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrrheum.2012.16","article-title":"Validated methods for assessment of subclinical atherosclerosis in rheumatology","volume":"8","author":"Kerekes","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","article-title":"Rheumatoid arthritis and metabolic syndrome","volume":"10","author":"Kerekes","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_6","first-page":"710928","article-title":"Metabolic syndrome in rheumatoid arthritis","volume":"2013","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e23666","DOI":"10.1002\/jcla.23666","article-title":"Metabolic syndrome in rheumatoid arthritis patients: Relationship among its clinical components","volume":"35","author":"Ojeda","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-018-8714-z","article-title":"Atherosclerosis in rheumatoid arthritis: Promoters and opponents","volume":"58","author":"Carbone","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/1570161117666190619143842","article-title":"Cardiovascular risk in rheumatoid arthritis and mechanistic links: From pathophysiology to treatment","volume":"18","author":"Fragoulis","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/eurheartj\/ehu403","article-title":"Cardiovascular disease in patients with chronic inflammation: Mechanisms underlying premature cardiovascular events in rheumatologic conditions","volume":"36","author":"Mason","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_11","first-page":"398","article-title":"Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: A multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity","volume":"35","author":"Kerekes","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: Results from the british society for rheumatology biologics register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrrheum.2009.219","article-title":"Vascular effects of biologic agents in ra and spondyloarthropathies","volume":"5","author":"Szekanecz","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in ra: A maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/ard.2006.059691","article-title":"Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis","volume":"66","author":"Peters","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: A randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00228-004-0820-6","article-title":"Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage","volume":"60","author":"Harangi","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_22","first-page":"214","article-title":"The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts","volume":"35","author":"Eckerson","year":"1983","journal-title":"Am. J. Hum. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/S0024-3205(03)00195-4","article-title":"Serum paraoxonase activity decreases in rheumatoid arthritis","volume":"72","author":"Tanimoto","year":"2003","journal-title":"Life Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s10067-006-0300-8","article-title":"Paraoxonase and arylesterase levels in rheumatoid arthritis","volume":"26","author":"Isik","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00296-012-2591-1","article-title":"Evaluation of paraoxonase and arylesterase activities in egyptian patients with ankylosing spondylitis","volume":"33","author":"Olama","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.25011\/cim.v34i4.15364","article-title":"Carotid intima-media thickness and paraoxonase activity in patients with ankylosing spondylitis","volume":"34","author":"Cece","year":"2011","journal-title":"Clin. Investig. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16848","DOI":"10.1038\/s41598-020-74016-w","article-title":"Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice","volume":"10","author":"Wang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39833","article-title":"Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial","volume":"69","author":"Lee","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"El-Banna, H., and Jiman-Fatani, A. (2014). Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis. BMC Musculoskelet. Disord., 15.","DOI":"10.1186\/1471-2474-15-379"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/ard.2008.092171","article-title":"Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients","volume":"68","author":"Popa","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/bjd.12144","article-title":"Oxidative stress and psoriasis: The effect of antitumour necrosis factor-alpha inhibitor treatment","volume":"168","author":"Bacchetti","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11883-005-0035-z","article-title":"The use of myeloperoxidase as a risk marker for atherosclerosis","volume":"7","author":"Nambi","year":"2005","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_33","first-page":"53","article-title":"Myeloperoxidase","volume":"7","author":"Winterbourn","year":"2000","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clinbiochem.2016.03.011","article-title":"Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications","volume":"49","author":"Koncsos","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00296-011-1810-5","article-title":"Increased myeloperoxidase plasma levels in rheumatoid arthritis","volume":"32","author":"Fernandes","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/rheumatology\/kes193","article-title":"Myeloperoxidase and oxidative stress in rheumatoid arthritis","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13075-016-1140-9","article-title":"Rheumatoid arthritis antigens homocitrulline and citrulline are generated by local myeloperoxidase and peptidyl arginine deiminases 2, 3 and 4 in rheumatoid nodule and synovial tissue","volume":"18","author":"Turunen","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/ard.53.1.24","article-title":"Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: Prevalence, clinical correlates, and igg subclass","volume":"53","author":"Cambridge","year":"1994","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrrheum.2011.107","article-title":"What\u2019s new in our understanding of the role of adipokines in rheumatic diseases?","volume":"7","author":"Gomez","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.atherosclerosis.2007.06.001","article-title":"Relationship of adiponectin to serum paraoxonase 1","volume":"197","author":"Bajnok","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.metabol.2007.06.022","article-title":"Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals","volume":"56","author":"Bajnok","year":"2007","journal-title":"Metabolism"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar3475","article-title":"Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis","volume":"13","author":"Kaneko","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3899\/jrheum.140122","article-title":"Circulating concentrations of the novel adipokine chemerin are associated with cardiovascular disease risk in rheumatoid arthritis","volume":"41","author":"Dessein","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Herenius, M.M., Oliveira, A.S., Wijbrandts, C.A., Gerlag, D.M., Tak, P.P., and Lebre, M.C. (2013). Anti-tnf therapy reduces serum levels of chemerin in rheumatoid arthritis: A new mechanism by which anti-tnf might reduce inflammation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057802"},{"key":"ref_45","first-page":"293","article-title":"Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: Potential cardiovascular protective role of il-6 inhibition","volume":"37","author":"Fioravanti","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_46","first-page":"222","article-title":"Anti-tnf-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis","volume":"27","author":"Berja","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-019-04497-0","article-title":"Effects of 1-year anti-tnf-alpha therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis","volume":"40","author":"Kerekes","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3899\/jrheum.100668","article-title":"Assessment of subclinical vascular disease associated with ankylosing spondylitis","volume":"38","author":"Kerekes","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3899\/jrheum.090667","article-title":"Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis","volume":"37","author":"Peters","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000112322","article-title":"Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease","volume":"25","author":"Harangi","year":"2008","journal-title":"Cerebrovasc. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"ref_52","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/jcmm.12282","article-title":"Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients","volume":"18","author":"Fulop","year":"2014","journal-title":"J. Cell Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1024\/0301-1526\/a000643","article-title":"Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers in overweight patients with newly diagnosed untreated hyperlipidaemia","volume":"46","author":"Varga","year":"2017","journal-title":"Vasa"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"R194","DOI":"10.1186\/ar4384","article-title":"Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis","volume":"15","author":"Kang","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sodergren, A., Karp, K., Bengtsson, C., Moller, B., Rantapaa-Dahlqvist, S., and Wallberg-Jonsson, S. (2019). Biomarkers associated with cardiovascular disease in patients with early rheumatoid arthritis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220531"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00508-019-01602-y","article-title":"Linking myeloperoxidase with subclinical atherosclerosis in adults with metabolic syndrome","volume":"132","author":"Iana","year":"2020","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clinbiochem.2008.01.017","article-title":"The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes","volume":"41","author":"Loimaala","year":"2008","journal-title":"Clin. Biochem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/ard.2005.046540","article-title":"Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis","volume":"65","author":"Otero","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_60","first-page":"921","article-title":"Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Kiortsis","year":"2006","journal-title":"J. Rheumatol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/10\/1535\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:17:12Z","timestamp":1760167032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/10\/1535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biom11101535"],"URL":"https:\/\/doi.org\/10.3390\/biom11101535","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]}}}